DFTX · Definium Therapeutics
AI read · Neutral
The AI's read
This leaves Definium's business picture unchanged. The update reports no new trial results or other company changes, so it adds no new evidence about how the business is doing.
Wells Fargo says to keep buying Definium Therapeutics shares and set a price target.
Neutral
Wells Fargo kept its Buy rating and $72 target, but reported no new trial results or company changes. The update adds no new business evidence to change how Definium looks.
Get alerts for DFTX
Follow Definium Therapeutics (DFTX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for DFTXFree on the App Store and Google Play, or on the web.